Novartis to Acquire IFM Tre for its Clinical and Preclinical Portfolio of NLRP3 Inhibitors for $1.5B

Shots: 

• Novartis acquires IFM Tre, in all stock transaction for $1.575B. IFM Tre to receive $310M upfront & $1.265B milestones from Novartis. The transaction is expected to close in Q2’19
• The focus of the acquisition is to expand Novartis’ immunomodulatory portfolio with the addition of IFM Tre’s one clinical (IFM-2427) and two preclinical programs of NLRP3 inhibitors targeting NLRP3 inflammasome to treat multiple metabolic, fibrotic, autoimmune, and neurological diseases
• IFM-2427 is a clinical stage antagonist targeted for chronic inflammatory disorders, including gout, atherosclerosis and nonalcoholic steatohepatitis (NASH)

Click here to read full press release/ article | Ref: IFM Therapeutics | Image: Twitter